Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Han Zeng

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
Oncoimmunology|September 14, 2020
Intratumoral CCR5<sup>+</sup> neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responsesZhuoyi Xiang, Quan Zhou, Han Zeng, et al.
Oncoimmunology|November 12, 2020
Tumor-infiltrating TNFRSF9<sup>+</sup> CD8<sup>+</sup> T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic responseYaohui Li, Zewei Wang, Wenbin Jiang, et al.
Cancer Research|February 16, 2020
Blockade of DC-SIGN<sup>+</sup> Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder CancerBaoying Hu, Zewei Wang, Han Zeng, et al.
International Journal of Cancer|October 5, 2019
Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responsesHan Zeng, Zheng Liu, Zewei Wang, et al.
Journal for Immunotherapy of Cancer|May 7, 2020
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinomaQuan Zhou, Yangyang Qi, Zewei Wang, et al.
Cancer Immunology, Immunotherapy : CII|May 6, 2020
CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancerTao Wang, Quan Zhou, Han Zeng, et al.
Oncoimmunology|September 17, 2020
Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5<sup>+</sup> CD8<sup>+</sup> T cell abundanceQiuren Huang, Quan Zhou, Hongyu Zhang, et al.
International Journal of Cancer|August 1, 2020
Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancerQuan Zhou, Hongyu Zhang, Zewei Wang, et al.
European Urology|September 25, 2023
Erratum to "Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion" [Eur. Urol. 75(5) (2019) 752-763]Qiang Fu, Le Xu, Yiwei Wang, et al.
European Urology|October 9, 2018
Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune EvasionQiang Fu, Le Xu, Yiwei Wang, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Oncoimmunology|September 14, 2020
Intratumoral CCR5<sup>+</sup> neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responsesZhuoyi Xiang, Quan Zhou, Han Zeng, et al.
Oncoimmunology|November 12, 2020
Tumor-infiltrating TNFRSF9<sup>+</sup> CD8<sup>+</sup> T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic responseYaohui Li, Zewei Wang, Wenbin Jiang, et al.
Cancer Research|February 16, 2020
Blockade of DC-SIGN<sup>+</sup> Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder CancerBaoying Hu, Zewei Wang, Han Zeng, et al.
International Journal of Cancer|October 5, 2019
Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responsesHan Zeng, Zheng Liu, Zewei Wang, et al.
Journal for Immunotherapy of Cancer|May 7, 2020
CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinomaQuan Zhou, Yangyang Qi, Zewei Wang, et al.
Cancer Immunology, Immunotherapy : CII|May 6, 2020
CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancerTao Wang, Quan Zhou, Han Zeng, et al.
Oncoimmunology|September 17, 2020
Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5<sup>+</sup> CD8<sup>+</sup> T cell abundanceQiuren Huang, Quan Zhou, Hongyu Zhang, et al.
International Journal of Cancer|August 1, 2020
Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancerQuan Zhou, Hongyu Zhang, Zewei Wang, et al.
European Urology|September 25, 2023
Erratum to "Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion" [Eur. Urol. 75(5) (2019) 752-763]Qiang Fu, Le Xu, Yiwei Wang, et al.
European Urology|October 9, 2018
Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune EvasionQiang Fu, Le Xu, Yiwei Wang, et al.
Pageof 13